Besides, to investigate the function of methylation activity of PRMT1 in cardiac hypertrophy and cardiac fibrosis, a pharmacological inhibitor that specifically targeted to PRMT1, named CID2818500, was employed in NRCMs [32]. The gene discussed is PRMT1; the disease is cardiac hypertrophy.